The Effect of Obesity on the State of Platelet-plasma Hemostasis in Patients with Essential Hypertension in Combination with Non-alcoholic Fatty Liver Disease

Authors

DOI:

https://doi.org/10.30841/2307-5112.4.2020.217657

Keywords:

hypertension, non-alcoholic fatty liver disease, obesity, platelet-plasma hemostasis

Abstract

Obesity, being one of the main modified risk factors for the development of pathology of the cardiovascular system, determines its rapid progression, more severe course and a high incidence of complications. With the prevalence of obesity, the incidence of hypertension (HT), non-alcoholic fatty liver disease (NAFLD), and, as a result, cardiovascular events increases.

The objective: To increase the efficiency of early diagnosis of thrombophilic changes in the blood in patients with essential hypertension and concomitant obesity, combined with non-alcoholic fatty liver disease.

Materials and methods. The study was conducted on the clinical base of the Department of Propedeutics of Internal Medicine No. 1 of the Bogomolets National Medical University in Kiev Clinical Hospital on railway transport No. 2 Branch «Center for Health Protection» of PJSC «Ukrainian Railway». 152 patients were examined: 72 men and 80 women. The patients were divided into groups: Group I – patients with stage II hypertension without signs of liver damage (46 people); Group II – patients with NAFLD without HT (54 people); Group III – patients with stage II HD with NAFLD (52 people).

Results. In the group of NAFLD patients without concomitant hypertension, the effect of obesity was observed both on the platelet count and on their mean volume. The platelet count was significantly higher in the presence of obesity – it was 16 % (<0.05) more, the MPV levels were also higher in NAFLD patients with a BMI ≥30 kg/m2 – by 2 % (p<0,05). The degree of adrenaline-induced aggregation was significantly increased only in obese patients –– by 40 % (p<0.001) compared with controls, and by 18 % with non-obese patients. During the exitox test in the NAFLD group in the obesity subgroup, a 9.5 % shortening of the clot formation time was revealed (p<0.05). In the group of combined course of NAFLD and HT II stage the division of patients by BMI made it possible to reveal the depression of anticoagulant activity of antithrombin III was less by 10.5 % (p<0.01), and protein C by 23.2 % (p<0.001) in obese patients.

Conclusion. Addition of obesity to hypertension and to the comorbid course of hypertension with NAFLD increased the thrombogenic activity of the blood, affecting various stages of hemostasis. However, the indicators of platelet-plasma hemostasis in patients with independent NAFLD did not actually differ from patients with obesity and BM I<30 kg/m2, which indicates similar pathophysiological mechanisms of prothrombotic changes in obesity and NAFLD.

Author Biographies

В. З. Нетяженко, Bogomolets National Medical University

Vasyl Z. Netyazhenko,

Department of Propedeutics of Internal Medicine No 1

Н. М. Баженова, Bogomolets National Medical University

Nataliia M. Bazhenova,

Department of Propedeutics of Internal Medicine No 1

References

Garvey W.T. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity / W.T. Garvey, J.I. Mechanick, E.M. Brett[et al.] // Endocrine Practice. – 2016. – Vol. 22, No. Supplement 3. – P. 1–203.

Lackland D.T. Global burden of cardiovascular disease and stroke: hypertension at the core / D.T. Lackland, M.A. Weber // Canadian Journal of Cardiology. – 2015. – Vol. 31, No. 5. – P. 569–571.

Jump D.B. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer / D.B. Jump, C.M. Depner, S. Tripathy, K.A. Lytle // Advances in Nutrition. – 2015. – Vol. 6, No. 6. – P. 694–702.

Friedman S.L. Mechanisms of nafld development and therapeutic strategies / S.L. Friedman, B.A. Neuschwander-Tetri, M. Rinella, A.J. Sanyal. – Nature Publishing Group, 2018.

Spinosa M. Nonalcoholic fatty liver disease-evidence for a thrombophilic state? / M. Spinosa, J.G. Stine // Current Pharmaceutical Design. – 2020. – Vol. 26, No. 10. – P. 1036–1044.

Cholankeril G. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes / G. Cholankeril, R.J. Wong, M. Hu [et al.] // Digestive Diseases and Sciences. – 2017. – Vol. 62, No. 10. – P. 2915–2922.

Noureddin M. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances / M. Noureddin, A. Vipani, C. Bresee[et al.] // American Journal of Gastroenterology. – 2018. – Vol. 113, No. 11. – P. 1649–1659.

Verrijken A. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis / A. Verrijken, S. Francque, I. Mertens[et al.] // Hepatology. – 2014. – Vol. 59, No. 1. – P. 121–129.

Stine J.G. Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to nonalcoholic steatohepatitis original contribution / J.G. Stine, B.A. Niccum, A.N. Zimmet[et al.] // Clinical and Translational Gastroenterology.– 2018. – Vol. 9, No. 3.

Stine J.G. Advanced non-alcoholic steatohepatitis cirrhosis: a high-risk population for pre-liver transplant portal vein thrombosis / J.G. Stine, C.K. Argo, S.J. Pelletier [et al.] // World Journal of Hepatology. – 2017. – Vol. 9, No. 3. – P. 139–146.

Pergola G. De Platelet number is positively and independently associated with glycated hemoglobin in non-diabetic overweight and obese subjects / G. De Pergola, V.A. Giagulli, E. Guastamacchia[et al.] // Nutrition, Metabolism and Cardiovascular Diseases. – 2019. – Vol. 29, No. 3.– P. 254–259.

Published

2020-10-30

Issue

Section

For practicing physicians